Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Has results × Digoxin × Clear all
NCT01162135 2025-05-04

Digoxin for Recurrent Prostate Cancer

Thomas Jefferson University

Phase 2 Completed
16 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT01763931 2020-01-31

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
6 enrolled 8 charts
Breast

Breast Neoplasms

NCT00281021 2018-03-29

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

University of Louisville

Phase 2 Terminated
26 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01887288 2018-02-22

Capecitabine With Digoxin for Metastatic Breast Cancer

Western Regional Medical Center

Phase 2 Terminated
16 enrolled 1 chart
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡